Cincera Therapeutics Pty Ltd. and Monash University co-presented the phenotypic drug discovery of CIN-244, a novel MRTF/SRF pathway inhibitor reported to be potentially useful for the treatment of fibrotic disease, particularly liver, lung and renal fibrosis.
Allorion Therapeutics (Guangzhou) Co. Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and systemic lupus erythematosus.
Humanwell Healthcare (Group) Co. Ltd. has prepared and tested 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of fibrosis, tissue injury and inflammatory disorders.
Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage response inhibitor, and it, too, is looking to raise a series A to take the program through to the end of phase I.
Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up for clinical development, and spinning them into startups, gathers pace. At the same time, Nodus Oncology Ltd., the first spinout created around an acquired asset, has just reached in vivo proof of concept with its lead DNA damage response inhibitor, and it, too, is looking to raise a series A to take the program through to the end of phase I.
Bristol Myers Squibb Co. has prepared and tested new Substituted benzimidazole compounds acting as Toll-like receptor 9 (TLR9) antagonists. They are reported to be useful for the treatment of fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), chronic kidney disease, cancer, primary sclerosing cholangitis, idiopathic pulmonary fibrosis, inflammatory and autoimmune diseases.
The nucleotide-binding oligomerization domain-like receptor pyrin domain containing 3 (NLRP3) inflammasome is an intracellular multiprotein complex that may be activated by exogenous or endogenous signals and is involved in the pathogenesis of several inflammatory disorders.
The risk of developing multiple sclerosis (MS) is nearly four times as high for women as it is for men. And that relative risk has increased sharply over time. In 1955, women were only slightly more likely than men to develop MS. A research team at the University of Toronto and the Oklahoma Medical Research Foundation (OMRF) has gained new insights into possible causes for this increasing disparity.
RSS
